Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific equity transactions related to the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Material Changes
On April 18, 2012, the Plan Administrators notified the Company of an increase in interests in American Depositary Shares (ADSs) for specific individuals following the re-investment of dividends paid on April 12, 2012. The transaction price was $44.74 per ADS.
- Mrs D P Connelly: Acquired 14.826 ADSs under the personal contribution element.
- Mr W C Louv: Experienced a notional increase of 15.143 ADSs (Company contribution) and acquired 38.938 ADSs (personal contribution). Additionally, a notional increase of 39.761 ADSs occurred under the matching element.
Outlook, Risks, and Unusual Items
The filing notes that the individuals participated in the Plan regarding their 2010 bonus on a post-tax basis. Notional dividends accrued under the matching element will be paid out proportionally based on the percentage of holdings that vest after the relevant three-year measurement period. No other risks, contingencies, or management outlook were disclosed in this specific document.
Investor Verification Points
- Verify the vesting schedule and conditions for the 2010 deferred annual bonus matching awards.
- Confirm the total number of ADSs held by the named directors post-transaction.
- Review the full terms of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan to understand payout mechanics.